Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dermatologists' Perspectives on Referral Systems and Legal Risk: Insights From a National Survey.

The Australasian journal of dermatology·2026
Same author

Plant Bioactive Compounds of Brazilian Pampa Biome Natural Grasslands Affecting Lamb Meat Quality.

Foods (Basel, Switzerland)·2024
Same author

Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin.

JAMA dermatology·2024
Same author

Field cancerisation and radiotherapy: a case of treatment complications.

The Medical journal of Australia·2023
Same author

A reply to 'Evaluation of dynamic dermoscopic features of melanoma and benign naevi by sequential digital dermoscopic imaging and total body photography in a high-risk Australian cohort'.

The Australasian journal of dermatology·2023
Same author

Reply to: Adler et al.'s Melanoma diagnosis at a specialist dermatology practice without the use of photographic surveillance.

The Australasian journal of dermatology·2023
Same journal

Benzalkonium Chloride in Eye Drops Causing Allergic Contact Dermatitis: A Case Series.

The Australasian journal of dermatology·2026
Same journal

The Dermatologist's Role in Early PMOS Diagnosis.

The Australasian journal of dermatology·2026
Same journal

From Curriculum Variation to Clinical Capability: Advancing Dermatology Education in Australia.

The Australasian journal of dermatology·2026
Same journal

Fatal Phenobarbital-Associated Toxic Epidermal Necrolysis With Severe Acute Kidney Injury and Multiorgan Failure: Prognostic Value of SCORTEN and ALDEN.

The Australasian journal of dermatology·2026
Same journal

Granulomatous Vasculitis: An Unusual Manifestation of Metastatic Crohn's Disease.

The Australasian journal of dermatology·2026
Same journal

The Rintala Advanced Modification (RAM) Flap: A Novel Technique for Off-Centre Nasal Reconstruction.

The Australasian journal of dermatology·2026
See all related articles

Related Experiment Video

Updated: May 19, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Hydroxyurea induced dermatomyositis-like eruption.

Tania M Zappala1, Karl Rodins, James Muir

  • 1Mater Misericordiae Hospital, Department of Dermatology, Brisbane, QLD 4101, Australia. taniazappala@gmail.com

The Australasian Journal of Dermatology
|August 14, 2012
PubMed
Summary
This summary is machine-generated.

Hydroxyurea (HU) can cause a rare skin condition resembling dermatomyositis (DM). Identifying this hydroxyurea-induced DM-like eruption (HU DM-LE) is crucial for proper patient management and avoiding unnecessary treatments.

Related Experiment Videos

Last Updated: May 19, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Area of Science:

  • Dermatology
  • Pharmacology
  • Internal Medicine

Background:

  • Medication-induced dermatomyositis (DM) is uncommon, with hydroxyurea (HU) identified as a frequent trigger.
  • Distinguishing drug-induced presentations from idiopathic DM is clinically significant.

Observation:

  • Hydroxyurea-induced DM-like eruption (HU DM-LE) presents with characteristic DM skin findings but lacks systemic involvement.
  • Concurrent cutaneous findings like xerosis, atrophy, stomatitis, ulcerations, and melanonychia are associated with HU use.

Findings:

  • HU DM-LE represents a distinct dermopathy linked to hydroxyurea therapy.
  • Cessation of hydroxyurea leads to the resolution of the DM-like eruption.

Implications:

  • Recognizing HU DM-LE aids in accurate diagnosis and avoids potentially harmful immunosuppressive therapies.
  • Considering medication etiology is paramount in patients presenting with dermatomyositis-like symptoms.